BACKGROUND AND OBJECTIVES: To detail the technique and evaluate the impact of a personal modified posterior reconstruction technique (PDR) on the outcomes of extrafascial laparoscopic radical prostatectomy (eLRP) in a consecutive series of 52 patients affected by high-risk prostate cancer (HRPCa).
METHODS: From October 2007 to March 2012, 52 patients underwent PDR during eLRP for HRPCa. Fifty-four patients who underwent eLRP for HRPCa with no PDR were considered as historical controls. Mean operative time (MOT), mean catheterization time (MCT), % continence and quality of life (QoL) at a scheduled follow-up, % anastomotic leakage, % adjuvant therapy were compared between the groups. Percentage of continence and QoL were prospectively assessed by self-administered validated questionnaires (ICI-Q-SF; SF-36) at 1, 3, 6, and12 months.
RESULTS: PDR was associated wither higher continence rates at 1 and 3 mo (P = .028, P = .006), a lower incidence of cystographic leakage (P = .002), and an increased adjuvant radiotherapy rate (P = .008). At 1- and 3-mo interval, in the PDR group, we found a higher number of patients reporting better general health, (P = .01, P = .03) reduced role limitations due to physical health, (P = .02, P = .001), and emotional problems (P = .001, P = .02).
CONCLUSIONS: PDR is associated with a lower degree of anastomotic leakage, and it significantly enhances urinary continence at 1 and 3 mo. The increased adjuvant radiotherapy rate and quality of life after surgery observed with our technique suggest that in the high-risk setting an early functional recovery may substantially influence the oncologic outcome of eLRP.
Written by:
Anceschi U1, Gaffi M2, Molinari C2, Anceschi C2 Are you the author?
1Department of Urology, Viale dei Colli Portuensi 579 - CAP 00151 Rome (Italy). Policlinico Tor Vergata, Viale Oxford 81 00133- Rome - Italy. . 2S. Camillo-Forlanini Hospital, Department of Urology, Rome, Italy.
Reference: JSLS. 2013;17(4):535-42
doi: 10.4293/108680813X13794522666365
PubMed Abstract
PMID: 24398194
UroToday.com Prostate Cancer Section
